Evidence map›Paper›PMID 34760717›Full record

ArticleFrontiers in cellular and infection microbiology2021

Structure-Based Primer Design Minimizes the Risk of PCR Failure Caused by SARS-CoV-2 Mutations.

Hongjie Dong, Shuai Wang, Junmei Zhang, Kundi Zhang, Fengyu Zhang, Hongwei Wang, Shiling Xie, Wei Hu, Lichuan Gu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. The Mutational Landscape of SARS-CoV-2.International journal of molecular sciences · 2023
    Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hongjie DongState Key Laboratory of Microbial Technology, Shandong University, Qingdao, China.
Shuai WangState Key Laboratory of Microbial Technology, Shandong University, Qingdao, China.
Junmei ZhangState Key Laboratory of Microbial Technology, Shandong University, Qingdao, China.
Kundi ZhangState Key Laboratory of Microbial Technology, Shandong University, Qingdao, China.
Fengyu ZhangState Key Laboratory of Microbial Technology, Shandong University, Qingdao, China.
Hongwei WangState Key Laboratory of Microbial Technology, Shandong University, Qingdao, China.
Shiling XieResearch and Development Department, Shandong Shtars Medical Technology Co., Ltd, Jinan, China.
Wei HuState Key Laboratory of Microbial Technology, Shandong University, Qingdao, China.
Lichuan GuState Key Laboratory of Microbial Technology, Shandong University, Qingdao, China.
Shandong University · CNState Key Laboratory of Microbial Technology

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) has caused and is still causing tremendous damage to the global economy and human health. Qualitative reverse transcription-PCR (RT-qPCR) is the golden standard for COVID-19 test. However, the SARS-CoV-2 variants may not only make vaccine less effective but also evade RT-qPCR test. Here we suggest an innovative primer design strategy for the RT-qPCR test of SARS-CoV-2. The principle is that the primers should be designed based on both the nucleic acid sequence and the structure of the protein encoded. The three nucleotides closest to the 3' end of the primer should be the codon which encodes the tryptophan in the structure core. Based on this principle, we designed a pair of primers targeting the

Indexed as

COVID-19SARS-CoV-2HumansMutationReal-Time Polymerase Chain ReactionRNA, ViralSensitivity and SpecificityRNA, Viralfalse-negativequantitative reverse-transcription PCRSARS-CoV-2thermal stabilityvariants

Identifiers

PMID34760717
PMCPMC8573093
OpenAlexW3211278677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.